Литература

1. EC∕IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. N EnglJ Med 1985;313:1191-1200.

2. Mayberg M.R., Wilson E., Yatsu E, Weiss D.G., Messina L., Hershey L.A., Coiling C., Eskridge J., Deykin D., Winn H.R.

3. Opie on the heart [Editorial]. Lancet 1980; 1:692.

4. Rubenstein L.Z., Robbins A.S., Josephson K.R., Schulman B.L, Osterweil D. The value of assessing falls in an elderly population. A randomized controlled trial. Ann Intern Med 1990; 113:308-316.

5. Fischer R.W. Comparison of antipruritic drugs administered orally. JAMA 1968;203:418-419.

6. Ziegler EJ., et al. Treatment of gram negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. New EnglJ Med 1991; 324:429-436.

7. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N EnglJ Med 1980;303:1038-1041.

8. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. 1. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.

9. Byington R.P., et al. Assessment of double-blindness at the conclusion of the beta-blocker heart attack trial. JAMA 1985;253:1733-1736.

10. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the con­sequences of treatment. New EnglJ Med 1988;318:1728-1733.

11. Naylor C.D., Chen E., Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-921.

12. Malenka DJ., Baron J.A., Johansen S., Wahrenberger J.W, Ross J. The framing effect of rela­tive and absolute risk.

13. McNeil B.J., Pauker S.G., Sox H.C. Jr., Tversky A. On the elicitation of preferences for alter­native therapies.. New EnglJ Med 1982;306:1259.

14. Sackett D.L, Gent M. Controversy in counting and attributing events in clinical trials. N Engl JMed 1979;301:1410-1412.

15. Steering Committee of the Physicians' Health Study Research Group Final report of the aspirin component of the ongoing Physicians' Health Study. New EnglJ Med 1989;321:129-135.

16. Guyatt G., Sackett D., Taylor D.W., ChongJ., Roberts R., Pugsiey S. Determining optimal therapy-randomized trials in individual patients. N EnglJ Med 1986;314:889-892.

17. Feinstein A.R., Sosin D.M., Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. New Engl J Med 1985;312:1604-2608.

18. Sacks H., Chalmers TC., Smith H. Jr. Randomized versus historical controls for clinical trials. AmJ Med 1982;72:233-240.

19. Topol EJ., Califf R.M. Scorecard cardiovascular medicine. Its impact and future direction. Ann Intern Med 1994;120:65-70.

20. Ropes М. Systemic lupus erythematosus. Cambridge, MA: Havard University Press, 1976.

21. Spilker B. Guide to clinical interpretation of data. New York: Raven Press, 1986.

Рекомендуемая литература

Chalmers T.C., Smith H. Jr, Blackburn B., Silverman B., Schroeder B., Reitman D., Ambroz A. A method for assessing the quality of a randomized control trial. Control Clin Trials 1981;2*31 -49.

Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont. How to read clinical journals. V: To distinguish useful from useless or even harmful therapy. Can Med AssocJ 1981;124:1156-1162.

DerSimonian R., Charette LJ., McPeek B., Mosteller E Reporting on methods in clinical trials. N EnglJ Med 1982;306:1332-1337.

Feinstein A.R. An additional basic science for clinical medicine. II: The limitations of randomized trials.

Friedman LM., Furberg C.D., De Mets D L Fundamentals of clinical trials, 2nd ed. Littleton, MA^, John Wright PSG, 1985

Guyatt G.H., Sackett D.L., Cook DJ. How to read Clinicaljournals. II: How to use an article about therapy or prevention A^, Are the results of the study valid? JAMA 1993;270:2598-2601.

Guyatt G.H., Sackett D.L, Cook DJ. How to read clinical journals. II: How to use an article about therapy or prevention. B^, What were the results and will they help me in caring for my patients'? JAMA 1994;271:59-63.

Guyatt G., Sackett D., Taylor D W, ChongJ., Roberts R., Pugsley S. Determining optimal therapy- randomized trials in individual patients N EnglJ Med 1986;314:889- 892.

Hellman S, Hellman D.S. Of mice and men. Problems of the randomized clinical trial. New EnglJ Med 1991;324:1585-1589.

Laupakis A., Wells G., Richardson S., Tugwell P. Users’ guide to the medical literature. V: How to use an article about prognosis. 1994; 272:234-237.

Lavori P.W, Louis T A., Bailar J.C. III., Polansky M. Design for experiments-parallel comparisons of treatment. N EnglJ Med 1983;309:1291-1298.

Meinert C L. Clinical trials* design, conduct and analysis. New York: Oxford University Press, 1986. Mostelller F., Gilbert J.P., McPeek B. Reporting standards and research strategies for controlled tri­als. Control Clin Trials 1980; 1:37-58

Oxman A.D., Guyatt G.H. A consumer's guide to subgroup analysis. Ann Intern Med 1992; 116^,78-84. Peto R, Pike M.C., Armitage P, Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K.,

PetoJ., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged obser­vation of each patient, part 1. BrJ Cancer 1976;34:585-612.

Peto R., Pike M.C., Armitage P, Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K, PetoJ , Smith PG. Design and analysis of randomized clinical trials requiring prolonged obser­vation of each patient, part 2. BrJ Cancer 1977;35:1-39.

Pocock S.J. Clinical trials: a practical approach. New YorkjJohn Wiley & Sons, 1983.

Yusuf S., Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3:409-420.